Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

International Journal of Obesity Pub Date : 2026-07-20 DOI:10.1038/s41366-026-02159-3

Claudia R Villatoro Santos, Hector D Estrada Tock, Haoran Tang, Laura N McEwen, Andrew Kraftson, William H Herman, Amy E Rothberg

{"title":"Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery.","authors":"Claudia R Villatoro Santos, Hector D Estrada Tock, Haoran Tang, Laura N McEwen, Andrew Kraftson, William H Herman, Amy E Rothberg","doi":"10.1038/s41366-026-02159-3","DOIUrl":null,"url":null,"abstract":"Objective: To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.Methods: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.Results: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9-27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3-21.4) and those without prescriptions (19.6%, 95% CI: 18.1-21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.Conclusion: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41366-026-02159-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.

Methods: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.

Results: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9-27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3-21.4) and those without prescriptions (19.6%, 95% CI: 18.1-21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.

Conclusion: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.

查看原文本刊更多论文

在接受减肥手术的患者中营养刺激激素治疗的使用和结果。

目的：描述营养刺激激素（NuSH）治疗对减肥的影响，包括减肥手术类型、糖尿病状况和初始NuSH处方时间。方法：回顾性研究2015年至2022年间在单一学术医疗中心接受减肥手术的1638名成年人。从电子健康记录中获得基线人口统计数据、NuSH治疗处方和随访体重。我们使用线性混合模型计算了总重量损失百分比（%TWL）随时间的变化。结果：接受Roux-en-Y胃旁路术（RYGB）的患者比接受袖式胃切除术（SG）的患者有更高的TWL %。与糖尿病患者相比，无糖尿病患者的TWL百分比更高。在72个月时，术前和术后均使用NuSH处方的患者调整后平均%TWL最高（22.7%,95% CI: 17.9-27.5），其次是术后仅使用处方的患者（19.9%,95% CI: 18.3-21.4）和未使用处方的患者（19.6%,95% CI: 18.1-21.2）。术后6个月内开处方的患者TWL百分比最高。结论：接受RYGB和没有糖尿病的个体TWL的百分比最高。术前、术后均接受NuSH处方和早期开始使用NuSH与TWL的最大百分比相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Obesity 医学-内分泌学与代谢

CiteScore

10.00

自引率

2.00%

发文量

221

审稿时长

3 months

期刊介绍： The International Journal of Obesity is a multi-disciplinary forum for research describing basic, clinical and applied studies in biochemistry, physiology, genetics and nutrition, molecular, metabolic, psychological and epidemiological aspects of obesity and related disorders. We publish a range of content types including original research articles, technical reports, reviews, correspondence and brief communications that elaborate on significant advances in the field and cover topical issues.